Form 8-K - Current report:
SEC Accession No. 0001213900-22-058035
Filing Date
2022-09-22
Accepted
2022-09-22 16:45:24
Documents
15
Period of Report
2022-09-22
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea166159-8k_citiuspharma.htm   iXBRL 8-K 31245
2 PRESS RELEASE DATED SEPTEMBER 22, 2022. ea166159ex99-1_citiuspharma.htm EX-99.1 14666
7 GRAPHIC image_001.jpg GRAPHIC 4477
  Complete submission text file 0001213900-22-058035.txt   275567

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ctxr-20220922.xsd EX-101.SCH 3985
4 XBRL DEFINITION FILE ctxr-20220922_def.xml EX-101.DEF 26596
5 XBRL LABEL FILE ctxr-20220922_lab.xml EX-101.LAB 36574
6 XBRL PRESENTATION FILE ctxr-20220922_pre.xml EX-101.PRE 25220
9 EXTRACTED XBRL INSTANCE DOCUMENT ea166159-8k_citiuspharma_htm.xml XML 5357
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 221259713
SIC: 2834 Pharmaceutical Preparations